In melanoma and bladder cancer, Low methylation of the NLRC5 promoter is associated with higher survival rate (51).Therefore, the NLRC5 methylation network plays a role in diseases and immunity, and its relationship with CNS diseases and specific disease mechanisms needs to be further elucidated. Here, NLRC5 is linked to urinary bladder cancer.